Patient reported outcomes in Triple Class Exposed, Relapsed/Refractory Multiple Myeloma (TCE RRMM) patients in KarMMa 3 trial (Phase 3 RCT): idecabtagene Vicleucel (ide-cel) versus standard regimens

被引：0

作者：

Einsele, H. ^{[1
]}

Delforge, M. ^{[2
]}

Patel, K. ^{[3
]}

Eliason, L. ^{[4
]}

Dhanda, D. ^{[4
]}

Shi, L. ^{[5
]}

Guo, S. ^{[5
]}

Marshall, T. ^{[4
]}

Arnulf, B. ^{[6
]}

Cavo, M. ^{[7
]}

Nooka, A. ^{[8
]}

Manier, S. ^{[9
]}

Callander, N. ^{[10
]}

Giralt, S. ^{[11
]}

Ailawadhi, S. ^{[12
]}

McKiver, Popa M. ^{[4
]}

Cook, M. ^{[13
]}

Rodriguez Otero, P. ^{[14
]}

机构：

[1] Uniklinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[2] Univ Hosp Leuven, Leuven, Belgium

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Bristol Myers Squibb, Princeton, NJ USA

[5] Evidera, Bethesda, MD USA

[6] Hop St Louis, Paris, France

[7] Bologna Univ, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

[8] Emory Univ, Winship Canc Inst, Atlanda, GA USA

[9] Ctr Hosp Univ Lille, Lille, France

[10] Univ Wisconsin Hlth, Madison, WI USA

[11] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[12] Mayo Clin, Jacksonville, FL 32224 USA

[13] Celgene Int Sarl, Boudry, Switzerland

[14] Clin Univ Navarra, Pamplona, Spain

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V545

引用

页码：83 / 83

页数：1

共 50 条

[11] Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Analysis of Cytopenias and Infections in Pts from KarMMa-3
Baz, Rachid
Otero, Paula Rodriguez
Ailawadhi, Sikander
Arnulf, Bertrand
Patel, Krina K.
Nooka, Ajay K.
Costa, Luciano
Raje, Noopur S.
Abrahamsen, Ingerid Weum
Delforge, Michel
Gergis, Usama
Sborov, Douglas W.
Giralt, Sergio A.
Raab, Marc S.
Ishida, Tadao
Varshavsky-Yanovsky, Asya
Choi, Taewoong
Larry, Anderson D., Jr.
Truppel-Hartmann, Anna
Bhatnagar, Rashmi
Wu, Fan
Piasecki, Julia
Felten, Jasper
Caia, Andrea
Cook, Mark
Lin, Yi
BLOOD, 2023, 142
[12] Health related quality of life (HRQoL) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM) treated with idecabtagene vicleucel (ide-cel) versus standard regimens: Patient-reported outcomes (PROs) from KarMMa-3 phase 3 randomized controlled trial (RCT).
Delforge, Michel
Patel, Krina K.
Eliason, Laurie
Dhanda, Devender
Shi, Ling
Guo, Shien
Marshall, Thomas
Arnulf, Bertrand
Cavo, Michele
Nooka, Ajay K.
Manier, Salomon
Callander, Natalie Scott
Giralt, Sergio
Einsele, Hermann
Ailawadhi, Sikander
McKiver, Mihaela Popa
Cook, Mark
Rodriguez-Otero, Paula
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[13] Idecabtagene vicleucel (ide-cel) vs standard regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 analysis in high-risk subgroups
Raab, Marc S.
Patel, Krina
Rodriguez-Otero, Paula
Manier, Salomon
Baz, Rachid
Cavo, Michele
Callander, Natalie
Costa, Luciano J.
Moreau, Philippe
Solomon, Scott R.
Chen, Christine
Raje, Noopur
Scheid, Christoph
Delforge, Michel
Larsen, Jeremy
Pabst, Thomas
Suzuki, Kenshi
Truppel-Hartmann, Anna
Piasecki, Julia
Felten, Jasper
Caia, Andrea
Cook, Mark
Giralt, Sergio
Mateos, Maria-Victoria
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 144 - 144
[14] Idecabtagene vicleucel (ide-cel) versus standard regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 analysis in the modified intent-to-treat (mITT) population
Scheid, Christoph
Manier, Salomon
Ailawadhi, Sikander
Rodriguez-Otero, Paula
Arnulf, Bertrand
Patel, Krina
Solomon, Scott R.
Baz, Rachid
Jagannath, Sundar
Raje, Noopur
Mateos, Maria-Victoria
Abdallah, Al-Ola
Einsele, Hermann
Giralt, Sergio
Pabst, Thomas
Perrot, Aurore
Lin, Yi
Truppel-Hartmann, Anna
Bhatnagar, Rashmi
Felten, Jasper
Caia, Andrea
Piasecki, Julia
Cook, Mark
Moreau, Philippe
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 142 - 142
[15] Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma
Mancuso, Katia
Barbato, Simona
Talarico, Marco
Tacchetti, Paola
Zamagni, Elena
Cavo, Michele
EXPERT OPINION ON BIOLOGICAL THERAPY, 2025, 25 (01) : 27 - 46
[16] Idecabtagene Vicleucel (ide-cel) in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): the 5-year Follow-Up Analysis from KarMMa
Anderson, Larry
San-Miguel, Jesus
Martin, Thomas
Jagannath, Sundar
Berdeja, Jesus G.
Lonial, Sagar
Raje, Noopur
Lin, Yi
Siegel, David
Oriol, Albert
Moreau, Philippe
Yakoub-Agha, Ibrahim
Ishida, Tadao
Truppel-Hartmann, Anna
Chaudhry, Maria
Masciulli, Arianna
Peeramsetti, Sharavi
Wu, Fan
Shamsuzzaman, Md
Thompson, Ethan
Martin, Nathan
Campbell, Timothy
Munshi, Nikhil
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S81 - S82
[17] Ide-cel versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 analysis in the modified intention to-treat (mITT) population
Manier, Salomon
Ailawadhi, Sikander
Rodriguez-Otero, Paula
Arnulf, Bertrand
Patel, Krina
Solomon, Scott
Baz, Rachid
Jagannath, Sundar
Raje, Noopur
Scheid, Christoph
Mateos, Maria-Victoria
Abdallah, Al-Ola
Einsele, Hermann
Giralt, Sergio
Pabst, Thomas Mueller
Perrot, Aurore
Lin, Yi
Truppel-Hartmann, Anna
Bhatnagar, Rashmi
Felten, Jasper
Caia, Andrea
Piasecki, Julia
Cook, Mark
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S51 - S51
[18] Effects of Idecabtagene Vicleucel ( Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Triple-Class-Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Who Received at Least 3 Lines of Prior Antimyeloma Regimens in the KarMMa-3 Phase 3 Randomized Controlled Trial
Delforge, Michel
Patel, Krina K.
Eliason, Laurie
Dhanda, Devender
Shi, Ling
Guo, Shien
Marshall, Thomas S.
Arnulf, Bertrand
Cavo, Michele
Nooka, Ajay K.
Manier, Salomon
Callander, Natalie S.
Giralt, Sergio A.
Einsele, Hermann
Ailawadhi, Sikander
Popa-McKiver, Mihaela
Cook, Mark
Otero, Paula Rodriguez
BLOOD, 2023, 142
[19] External Control Analysis for KarMMa-3: Idecabtagene Vicleucel (ide-cel) vs Real-World Standard of Care (RW SoC; COTA) for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
Lee, Hans
Towle, Kevin
Cope, Shannon
Liu, Sichen
Chen, Jenny
Jagannath, Sundar
Ailawadhi, Sikander
Marshall, Thomas
Acheampong, Teofilia
Dhanda, Devender
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S66 - S67
[20] Baseline and early post-infusion biomarkers associated with optimal response to idecabtagene vicleucel (ide-cel) in the KarMMa-3 study of triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM).
Piasecki, Julia
Desai, Keyur
Courtney, Carolyn
Thompson, Ethan
Pratt, Jim
Raje, Noopur S.
Patel, Krina K.
Raab, Marc S.
Cook, Mark
Simonsen, Katy L.
McKiver, Mihaela Popa
Kaiser, Shari
Martin, Nathan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →